

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/31061 A1

(51) International Patent Classification: C12Q 1/68

102-209, Dongjin-villa, 341, Chang-1-dong, Dobong-ku,
Seoul 132-909 (KR).

(21) International Application Number: PCT/KR00/01223

(74) Agents: YOON, Dong, Yoi et al.; Yoon & Lee International Patent & Law Office, 9th Fl., Yeosam Bldg., 648-23, Yoksam-dong, Kangnam-ku, Seoul 135-081 (KR).

(22) International Filing Date: 27 October 2000 (27.10.2000)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Date: 27 October 1999 (27.10.1999) KR
1999/46795

(71) Applicant: ERUME BIOTECH CO., LTD. (KR/KR);
4th Floor, Erume Building, 807-3, Bangbae-dong, Seocho-ku, Seoul 137-060 (KR).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: LEE, Hyeyoung; No. 190-1106, Woosung Apartment, Yangjae-1-dong, Seocho-ku, Seoul 137-793 (KR). PARK, Young Kil; 534-1, Seongnam-dong, Joongwon-ku, Seongnam-si 4612-824, Kyunggi-do (KR).
BAI, Gil-Han; No. 129-805 Parktown, Naejeong-dong, Boondang-ku, Seongnam-si 463-080, Kyunggi-do (KR).
KIM, Sang-Jae; No. 310-103, Seonsoocheon Apartment, 89, Banglee-dong, Songpa-ku, Seoul 138-829 (KR).
CHO, Sang-Nae; No. 111-602, Hansin Apartment, 929, Mok-6-dong, Yangcheon-ku, Seoul 158-759 (KR).
KIM, Yuen; 56-10, Moonsan-ri, Moonsan-eup, Paju-si 413-904, Kyunggi-do (KR). PARK, Hee, Jung; No.

Published:

— With international search report.
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: *mpoB* GENE FRAGMENTS AND A METHOD FOR THE DIAGNOSIS AND IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOSIS MYCOBACTERIAL STRAINS

M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

200
150
100
50



WO 01/31061 A1

(57) Abstract: The present invention is related to *mpoB* gene fragments and method for the diagnosis and identification of *Mycobacterium tuberculosis* and non-tuberculosis *Mycobacterium* strains using *mpoB* gene and its fragments.

**rpoB GENE FRAGMENTS AND A METHOD FOR THE
DIAGNOSIS AND IDENTIFICATION OF
MYCOBACTERIUM TUBERCULOSIS AND NON-
TUBERCULOSIS MYCOBACTERIAL STRAINS**

5

FIELD OF THE INVENTION

The present invention is related to rpoB gene fragments and a method for the
10 diagnosis and identification of Mycobacterium tuberculosis and non-tubercuolosis
Mycobacterial strains using rpoB gene fragments.

BACKGROUND OF THE INVENTION

15 Since the early 1980s, there has been an increase in disease caused by
organisms called nontuberculous mycobacteria (NTM), which is the generic name for
mycobacteria other than *M. tuberculosis* and *M. leprae* (MOTT). They affect both
immune-competent and immune-compromised persons, and patients with the human
immunodeficiency virus (HIV) are known to be especially vulnerable. The most
20 frequent NTMs involved in disease cases are known to be *M. avium*, *M. intracellulare*,
M. scrofulaceum, *M. kansasii*, *M. fortuitum* complex, *M. chelonae*, *M. abscessus*, *M.*
szulgai, *M. malmoeense*, *M. marinum*, *M. ulcerans*, and *M. africanum*, *M. bovis* (28).
Clinical diagnosis and treatment of nontuberculous mycobacterial infections are an
increasingly frequent challenge to clinicians.

25 Currently, clinical diagnosis of mycobacteria to the species level is primarily
based on cultural and biochemical tests. These conventional tests take several weeks,
and the tests sometimes fail precise identification. The procedures for these tests are
complex, laborious, and are usually impeded by the slow growth of mycobacteria in
clinical laboratories. Additional methods, such as high-performance liquid

chromatography, gas-liquid chromatography, thin-layer chromatography (5, 21, 36), and DNA sequencing analysis (3, 4, 15, 16, 17, 19, 26, 31, 32) can differentiate mycobacteria to the species level, but these are labor-intensive and difficult to perform for routine use in many clinical laboratories.

5 In contrast to the above-mentioned techniques, recent molecular techniques employing PCR-amplified products offers an easy, rapid, and inexpensive way to identify several mycobacterial species in a single experiment. PCR-restriction fragment length polymorphism analysis (PRA) has been developed to target mycobacterial genes, which are present in all mycobacteria such as *hsp65* (7, 11, 25, 10 29, 30, 34, 35), 16S rRNA (2, 14, 37), and *dnaJ* (33). However, these techniques are still cumbersome since they require several enzyme digestions for species identification, and the results are not easy to interpret for species identification due to the limited size variation of DNA fragments after digestion.

On the other hand, probe-hybridization technique which employs DNA of the 15 clinical specimen and oligo-probe hybridization (8, 9, 10, 18, 20, 23) is a useful tool for direct and rapid identification of NTM species. However, commercial kits currently available in the market are very expensive, limited only to 5 mycobacterial species, and the identification of a single species requires an independent experiment.

20

SUMMARY OF THE INVENTION

The present invention provides DNA fragments including sequence SEQ. ID. NO. 1 to 4 and 6 to 24.

The present invention provides a method of identification of Mycobacterium 25 strain comprising the step of 1) digesting a DNA fragment which has one of the sequence Seq. ID. NO 1 to 4 to 24 with restriction enzyme to obtain DNA fragment length polymorphism pattern ; 2) isolating DNA fragment from microorganism to identify; 3) amplifying said DNA fragment; 4) digesting said amplified DNA fragment

with the same restriction enzyme in step 1) ; 5) obtaining DNA fragment length polymorphism pattern from DNA fragment in step 4) ; and 6) comparing DNA fragment length polymorphism pattern from step 1) with DNA fragment length polymorphism pattern from step 5).

- 5 Preferably, said restriction enzymes are enzyme HaeIII, MspI, Sau3A1 or BstEII.

Preferably, the DNA fragment length polymorphism pattern from steps 1) and 5) is obtained by electrophoresis.

- And the Mycobacteria strain to be identified by this method are preferably *M. tuberculosis*, *M. avium*, *M. abscessus*, *M. flavescent*, *M. africanum*, *M. bovis*, *M. chelonae*, *M. celatum*, *M. fortuitum*, *M. gordonae*, *M. gastri*, *M. haemophilum*, *M. intracellulare*, *M. kansasii*, *M. malmoense*, *M. marinum*, *M. szulgai*, *M. terrae*, *M. scrofulaceum*, *M. ulcerans* or *M. xenopii*.

15

BRIEF DESCRIPTION OF THE DRAWINGS

- Fig. 1. (A). A diagram showing amplified region of the *rpoB* for PRA in this study. The primers PRO5' and RPO3' generates 360-bp PCR product, which locates upstream of *rif^r* region associated with resistance of *M. tuberculosis* to rifampin.
- 20 (B). An agarose gel (2%) with 360-bp PCR products using PRO5' and RPO3'. Lane M. DNA size marker (100-bp ladder), lane 1: negative control (no DNA sample), lanes 2-11: PCR products with reference strains of mycobacteria.
- Fig. 2. An example of PRA results with reference strains of mycobacteria using a set of primers (RPO5' and RPO3'). Amplified DNA was digested using both (A) *Msp* I and (B) *Hae* III restriction enzymes, and run on a 4% Metaphore agarose gel. Lane M: DNA size marker (50-bp ladder), lane 1: *M. gordonae* type IV, lane 2: *M. szulgai*, lane 3: *M. kansasii* type I, lane 4: *M. gallinarum*, lane 5: *M. avium*, lane 6: *M.*

scrofulaceum, lane 7: *M. asiaticum*, lane 8: *M. chelonae*, lane 9: *M. moriokaese*, lane 10: *M. phlei*, lane 11: *M. pulveris*, lane 12: *M. fortuitum* type I, lane 13: *M. austroafricanum*, lane 14: *M. smegmatis*, lane 15: *M. marinum*.

5 Fig. 3. PRA results with clinical isolates that have been identified by conventional methods, including microbiological and biochemical tests. PCR products were digested with *Msp* I enzyme and electrophoresed on 4% Metaphore agarose gel. Strains were clinical isolates of (A) *M. kansasii*, (B) *M. tuberculosis*, and (C) *M. chelonae* complex that include *M. chelonae* sub. *chelonae* and *M. chelonae* sub
10 *abscessus*.

Fig. 4. An algorithm was constructed based on the results of PRA with 40 mycobacterial reference strains and 3 other related bacterial strains. The PRA results of 10 other mycobacterial reference strains are not listed in this figure to make the
15 algorithm concise.

Fig. 5. An example of the application of *rpoB*-based PRA for the species identification of mycobacterial clinical isolates in clinical laboratory. Clinical isolates were amplified using primers, RPO5' and RPO3', digested with *Msp* I, and
20 run on a 4% Metaphore agarose gel. A DNA size marker (lane M: 50-bp ladder) and the PRA result of *M. bovis* was used as an internal size marker (lane 16) for each test. Using the algorithm in Fig. 3, these clinical isolates were determined to be *M. intracellulare* (lanes 1-6, 8, 9, 11-15), *M. gordonae* type II (lane 7), and *M. abscessus* (lane 10).

25

Fig. 6. Sequence alignment of the *rpoB* region amplified using a set of primers RPO5' and RPO3' from 35 different mycobacterial species. Sequences were aligned using multi-align program(6). Dashed lines represent nucleotide gaps.

Fig. 7. Examples of PCR-dot blot hybridization experiments. A total of 48 PCR products generated by using primers, RPO5, and RPO3', and DNAs from 48 mycobacterial species were blotted on the membrane, and an oligonucleotide probe which is specific to a certain mycobacterial species was hybridized at conditions described in the Materials and Methods section. Blotted DNAs on the membrane were as following; 1: *M. tuberculosis*, 2: *M. scrofulaceum* 3: *M. szulgai*, 4: *M. gastri*, 5: *M. kansasii* type I, 6: *M. kansasii* type II, 7: *M. kansasii* type III, 8: *M. kansasii* type IV, 9: *M. kansasii* type V, 10: *M. terrae*, 11: *M. avium*, 12: *M. intracellularea*, 13: *M. africanum*, 14: *M. celatum* type I, 15: *M. celatum* type II, 16: *M. haemophilum*, 17: *M. malmoeense*, 18: *M. bovis*, 19: *M. chelonae*, 20: *M. abscessus*, 21: *M. ulcerans*, 22: *M. marinum*, 23: *M. genevansae*, 24: *M. simiane*, 25: *M. flavescentis*, 26: *M. fortuitum* type I, 27: *M. fortuitum* type II, 28: *M. peregrinum*, 29: *M. triviale*, 30: *M. phlei*, 31: *M. parafortuitum*, 32: *M. vaccae*, 33: *M. aurum*, 34: *M. neoaurum*, 35: *M. fallax*, 36: *M. xenopi*, 37: *M. aichiense*, 38: *M. mucogenicum*, 39: *M. nonchromogenicum*, 40: *M. senegalense*, 41: *M. smegmatis*, 42: *M. thermoresistable*, 43: *M. intermedium*, 44: *M. gordonae* type I, 45: *M. gordonae* type II, 46: *M. gordonae* type III, 47: *M. gordonae* type IV, 48: *M. bovis*, BCG

DETAILED DESCRIPTION OF THE INVENTION

Mycobacterial identification to the species level is not only of academic interest but also is important because it provides a great deal of useful information on the epidemiology and pathogenesis of the organism, suggesting potential intervention strategies including successful treatment of patients on the clinical base. It is therefore important to develop methods that are rapid and simple, but yet precise and cost-effective to be used in a wide variety of clinical laboratories around the world. Currently available methods for differentiation of mycobacteria to the species level are

time-consuming evaluations using phenotypic and biochemical tests or laborious procedures using expensive equipment.

As compared to other molecular methods, the PRA method certainly fits these requirements better. It is rapid and precise since it employs PCR, and simple and cost-effective since it does not require any expensive equipment or laborious processes and can differentiate numerous species of mycobacteria within a single experiment. Owing to these advantages, several PRA methods based on different genes of mycobacteria have been developed (2, 7, 11, 14, 25, 29, 30, 33, 34, 35, 37). However, most of those methods require use of more than two enzymes to differentiate mycobacteria at the species level, and require computer-assisted software program to differentiate restriction fragments since the profiles of certain mycobacterial species were not distinctive enough for bare-eye interpretation.

The new PRA method developed through this invention has more advantages than the previous ones. As presented in Fig. 1, it is apparent that most of the species harbor unique PRA profiles. Unlike other PRA profiles, which may need computer-assisted analysis and interpretation of the gels, we do not face problems in resolving all the patterns obtained during the experiments. Furthermore, problems including gel-to-gel variations or confusion with the size of the restriction fragments were limited with the use of 50-bp size marker and PRA profile of *M. bovis* as an internal size marker.

On the other hand, the four members of the *M. tuberculosis* complex that are difficult to separate by using other methods such as sequence analysis or HPLC of mycolic acids were also undistinguishable by PRA method, confirming that they do belong to a genetically similar group. However, unlike other methods, this new PRA method can further differentiate *M. africanum* from other *M. tuberculosis* complex by *Sau* 3AI digestion. Therefore, in case the clinical isolate shows the *M. tuberculosis* complex profiles, PCR products can be further processed to differentiate *M. africanum* from other *M. tuberculosis* complex by *Sau* 3AI digestion. In addition, *M.*

tuberculosis and *M. bovis* can be differentiated by PCR amplification using *esat-6* gene derived PCR primers, which is known to be present only in the genome of *M. tuberculosis*.

Currently in our laboratory, a substantial number of mycobacterial clinical isolates have now been identified by our new PRA method in parallel with other reference methods, including conventional tests and molecular biological methods such as PRA based on *hsp65* gene and sequence analysis based on the *rpoB* gene. As a conclusion of this experiment, it is certain that this new PRA is a rapid, cost-effective, and efficient method for the identification of mycobacteria in a clinical microbiology laboratory. The whole procedure can be done in 2 days when culture is used. PRA has been successful when using a loopful of culture taken from solid media or using 100 μ l taken from liquid culture such as MGIT for mycobacterial species identification. Both of systems work well even with genomic DNA simply boiled for 5 min.

In addition to the PRA, PCR-dot blot and PCR-reverse dot blot hybridization method employing oligonucleotide probes that are highly specific to each mycobacterial species were also shown to be valuable techniques for simple and rapid identification of mycobacterial species. The oligonucleotides developed in this study were highly species-specific, thus indicating a usefulness of these probes in development of mycobacterial identification system which can be useful in clinical settings.

To develop new molecular techniques that are easier and more precise for mycobacterial species identification than currently available ones, we chose the *rpoB* gene that encodes β subunit of RNA polymerase. The information-rich nature of the *rpoB* gene has been recently employed in differentiation of mycobacteria by DNA hybridization array (10) or by DNA sequence analysis (16). However, the *rpoB* region used in these previous studies has limited sequence variation that can be used for species identification of mycobacteria. In the present study, we extended the

genetic knowledge of the *rpoB* gene to the highly polymorphic region that is suitable for developing mycobacterial species identification system using molecular biological techniques such as PRA and PCR-DNA hybridization. We also chose this region of the *rpoB* gene to be flanked by highly conserved sequences, thus can be suitable for
5 PCR amplification of the *rpoB* region of all mycobacterial species using the same set of PCR primers.

In this study, 50 reference strains representing 44 different mycobacterial species and 6 subspecies were used to amplify the 360-bp region of the *rpoB* gene. The PCR products were then subjected to restriction fragment length polymorphism
10 analysis (RFLP) to determine the efficacy of this region of the *rpoB* gene for mycobacterial species identification using PRA method. Subsequently, on the basis of PRA profiles generated with reference strains, an algorithm was generated, and a total of 260 clinical isolates were evaluated using new PRA method. In brief, the results clearly showed that this novel PRA method based on the *rpoB* gene generates
15 clear and distinctive results for easy, rapid, and precise identification of mycobacterial species that can be employed in clinical laboratories for prompt and accurate diagnosis.

Subsequently, PCR amplified regions of the *rpoB* gene derived from 30 mycobacterial species that are known to have clinical importance were sequenced. In
20 brief, results of sequence analysis showed that in the region of *rpoB* we amplified, highly polymorphic and species-specific regions exist, and thus indicated the usefulness of these regions for developing a new PCR-dot blot hybridization technique. On the basis of these sequence information, species-specific oligo-probes were designed and used to establish mycobacterial species identification system using
25 DNA hybridization techniques such as PCR-dot blot and PCR-reverse blot hybridization method.

The restriction analysis of a 360-bp fragment within *rpoB* gene after single *Msp* I digestion is highly effective for differentiating most of mycobacteria even at the

species level. Only several species require additional enzyme digestion such as *Hae* III, *Sau* 3AI, *Hinc* II, etc. For some species, such as *M. gordonae*, *M. kansasii*, *M. fortuitum*, and *M. celatum*, the discrimination was even obtained at the subtype level. For *M. kansasii*, this subdivision was clearly linked to genetic divergence observed previously by other investigators (1, 24, 27). It is therefore possible that using this PRA method, the discrimination at a subgroup level for other species could be similarly linked to bacteriological and clinical specificities.

Therefore, this invention provide a rpoB gene fragment(SEQ. ID. NO. 1 to 4 and 6 to 24) which has conserved sequence and polymorphic sequence between mycobacterial species.

Also this invention provide a method for diagnosis and identification of Mycobacterium tuberculosis and Non-tuberculosis Mycobacterium strain comprising the step of

- 1) digesting a DNA fragment which has one of the sequence Seq. ID. NO 1 to 24 with restriction enzyme to obtain DNA fragment length polymorphism pattern ;
 - 2) isolating DNA fragment from microorganism to identify;
 - 3) amplifying said DNA fragment using primer (SEQ. ID. NO. 25 and 26);
 - 4) digesting said amplified DNA fragment with the same restriction enzyme in step 1) ;
 - 5) obtaining DNA fragment length polymorphism pattern from DNA fragment in step 4) ; and
 - 6) comparing DNA fragment length polymorphism pattern from step 1) with DNA fragment length polymorphism pattern from step 5).
- Preferably, said restriction enzymes are enzyme *Hae*III, *Msp*I, *Sau*3AI or *Bst*EII.
- Preferably, the DNA fragment length polymorphism pattern from steps 1) and

5) is obtained by electrophoresis.

And the Mycobacteria strain to be identified by this method are listed in Table 1.

5 Though the present invention has been described with regard to its preferred embodiments, one skilled in the art will appreciate from a reading of this disclosure that various changes in form and detail can be made without departing from the scope and spirit of the invention.

10 EXAMPLES

MATERIALS and METHODS

Mycobacterial samples. A total of 50 mycobacterial reference strains
15 representing 44 mycobacterial species and 3 related species which belong to 2 different genera (Table 1) were used to develop the new PRA method in this study. Among them, 40 mycobacterial strains and 3 related species were obtained from the Korean Institute of Tuberculosis (KIT) and the Korean National Tuberculosis Association (KNTA) in Seoul, Korea. Four species were obtained from the Korean
20 Collection for Type Cultures (KCTC) at the Korean Research Institute of Bioscience & Biotechnology (KRIBB) and *M. abscessus*, which was recently separated from *M. chelonae* as an independent new species, was obtained from Department of Clinical Pathology at Yonsei University Medical College (YUMC). Five subtypes of *M. kansasii* were generously given by Dr. V. Vincent in the Laboratoire de Référence des
25 Mycobactéries, Institut Pasteur in France.

Clinical isolates subjected for PRA to evaluate the new method were obtained from KIT. All clinical isolates used in this study were identified on the basis of conventional tests that include microbiological characteristics and biochemical tests.

For some cases, strains were subjected for conventional PRA method based on *hsp65* gene (7, 35) to help precise identification of clinical isolates.

Table 1. Bacterial strains used in this study

5

	Species	Strain	Source
1	<i>M. abscessus</i>	Pettenkofer Inst.	YUMC
2	<i>M. africanum</i>	ATCC 25420	KIT
3	<i>M. arcinogenes</i>	ATCC 35753	KIT
4	<i>M. asiaticum</i>	ATCC 250276	KIT
5	<i>M. aurum</i>	ATCC 23366	KIT
6	<i>M. austroafricanum</i>	ATCC 33464	KRIBB
7	<i>M. avium</i>	ATCC 25291	KIT
8	<i>M. bovis</i>	ATCC 19210	KIT
9	<i>M. bovis</i> BCG	French Strain 1173P2	KIT
10	<i>M. celatum</i> type I/II	ATCC 51130/ATCC 51131	KIT
11	<i>M. chelonae</i>	ATCC 35749	KIT
12	<i>M. chitae</i>	ATCC 19627	KIT
13	<i>M. fallax</i>	ATCC 35219	KIT
14	<i>M. fortuitum</i> type I/II	ATCC 6841/ATCC 49404	KIT
15	<i>M. gallinarum</i>	ATCC 19710	KRIBB
16	<i>M. gastri</i>	ATCC 15754	KIT
17	<i>M. genavense</i>	ATCC 51233	KIT
18	<i>M. gilvum</i>	ATCC 43909	KIT
19	<i>M. gordonae</i>	ATCC 14470	KIT
20	<i>M. haemophilum</i>	ATCC 29548	KIT
21	<i>M. intracellulare</i>	ATCC 13950	KIT

22	<i>M. interjectum</i>	ATCC 51457	KIT
23	<i>M. intermedium</i>	ATCC 51848	KIT
24	<i>M. kansasii</i> type I-V		Pasteur Inst.
25	<i>M. malmoeense</i>	ATCC 29571	KIT
26	<i>M. marinum</i>	ATCC 927	KIT
27	<i>M. moriokaense</i>	ATCC 43059	KRIBB
28	<i>M. mucogenicum</i>	ATCC 49650	KIT
29	<i>M. neoaurum</i>	ATCC 25795	KIT
30	<i>M. nonchromogenicum</i>	ATCC 19530	KIT
31	<i>M. parafortuitum</i>	ATCC 19686	KIT
32	<i>M. peregrinum</i>	ATCC 14467	KIT
33	<i>M. phlei</i>	ATCC 11758	KIT
34	<i>M. pulveris</i>	ATCC 35154	KRIBB
35	<i>M. scrofulaceum</i>	ATCC 19981	KIT
36	<i>M. smegmatis</i>	ATCC 19420	KIT
37	<i>M. szulgai</i>	ATCC 35799	KIT
38	<i>M. terrae</i>	ATCC 15755	KIT
39	<i>M. thermoresistibile</i>	ATCC 19527	KIT
40	<i>M. triviale</i>	ATCC 23292	KIT
41	<i>M. tuberculosis</i> H37Rv	ATCC 27294	KIT
42	<i>M. ulcerans</i>	ATCC 19423	KIT
43	<i>M. vaccae</i>	ATCC 15483	KIT
44	<i>M. xenopi</i>	ATCC 19250	KIT
45	<i>N. brasiliensis</i>	ATCC 19296	KIT
46	<i>N. nova</i>	ATCC 21197	KIT
47	<i>R. equi</i>	ATCC 10146	KIT

DNA preparation. In order to prepare a DNA sample for PCR amplification, a

loopful of bacterial colony was taken from the Löwenstein-Jensen medium and resuspended in 400 μ l of distilled water in a screw-cap microcentrifuge tube. The sample was then boiled for 5 min, centrifuged for 5 min to settle down cell debris, and about 10 μ l of supernatant containing

5

PCR amplification.

The primer set used to amplify the region of the *rpoB* were 5'-TCAAGGAGAAGCGCTACGA-3' (RPO5') and 5'-GGATGTTGATCAGGGT CTGC-3' (RPO3') resulting in about 360-bp PCR product (base number 902 to 1261 and codon number 302 to 420 based on the sequence numbers for the *rpoB* gene of *M. tuberculosis* [GenBank accession No. p47766]. The primer sequences were selected from the region of the *rpoB* genes that have been previously identified from *M. tuberculosis*, *M. leprae*, and *M. smegmatis* (12, 13, 22). The primers were made to amplify the region between the variable region and conserved region based on the genetic information for the *rpoB* gene of *Escherichia coli*. As a result, PCR products included 171-bp of variable region and 189-bp of conserved region. Variable region was amplified in this experiment based on an assumption that the polymorphic nature of this region might help the clear distinction of each mycobacterial species using molecular biological techniques such as PRA and PCR-DNA hybridization. On the other hand, the region of the *rpoB* gene was also chosen to be flanked by highly conserved sequences, thus can be suitable for PCR amplification of the *rpoB* region of all mycobacterial species using the same set of PCR primers.

PCR was carried out in a final volume of 50 μ l with 10 μ l of DNA supernatant containing approximately 10 ng of genomic DNA, 10 pmole of each primers, 2 mM MgCl₂, 200 μ M of deoxynucleotide triphosphates, and 1 unit of DyNAzyme™II DNA polymerase (FINNZYMES, Espoo, Finland). DNA samples were first denatured completely by incubation at 94°C for 5 min before amplification cycle, then amplified using a cycle that includes (1) denaturation at 94°C for 1 min, (2)

primer annealing at 58°C for 1 min, and (3) elongation at 72°C for 1 min for 35 times using a Thermocycler (model 9600, Perkin Elmer). After the last amplification cycle, the samples were incubated further at 72°C for 7 min for complete elongation of the final PCR products. Positive and negative controls were always included in each PCR reaction. The positive control was the PCR mix with DNA of reference strain, *M. bovis*, and the negative control was the PCR mix without any DNA. After the PCR, the amplification results were visualized using 1.5% agarose gel electrophoresis and ethidium bromide staining.

10 **Restriction fragment length polymorphism analysis.** After successful amplification, the 360-bp long PCR products were subjected to restriction enzyme digestion. Most of the time, 16 μ l of PCR products (approximately 1 to 1.5 μ g of DNA) were digested in a 20 μ l of reaction volume using 5 units of *Msp* I (Boehringer Mannheim Biochemicals, Mannheim, Germany) and 2 μ l of 10X
15 reaction buffer supplied by manufacturer. Similarly, 16 μ l of PCR product was digested in a 20 μ l of reaction volume containing 5 units of *Hae* III enzyme (Takara Shuzo Co., LTD., Shiga, Japan) with the corresponding enzyme buffer. If necessary, additional enzyme digestions were carried out in a similar reaction condition. After 2 hours of incubation at 37°C, 4 μ l of gel loading buffer (0.25% bromophenol blue, 20 40% sucrose in water) was added, and the samples were loaded into a 4% metaphore agarose gel (FMC BioProducts, Rockland, Maine). Then, enzyme digested fragments were visualized by ethidium bromide staining and UV- light.

For the interpretation of the PRA profiles generated by each species, 50-bp ladder DNA size marker (Boehringer Mannheim, Germany) and the PRA profile of *M. bovis*, which generates about 175-bp, 80-bp, 60-bp, 40-bp restriction fragments, were used as an internal size marker. Using these size markers, the sizes of the restricted fragments of each species were determined, and an algorithm was made based on this information.

Cloning and sequence analysis. For sequence analysis, PCR products were purified by using a Geneclean kit (BIO101, Vista, Calif. USA) from an agarose gel and cloned into TOPO-TA cloning vector (Invitrogen Co., Carlsbad, CA) by the method recommended by the manufacturer. DNA sequencing was done by the dideoxy nucleotide-chain termination method (21) using ARL automatic sequencer (Pharmacia Biotech, Uppsala, Sweden). For each clone, M13 reverse primer and T7 promoter primer were used separately to read sequences from both directions. Sequences were aligned using a multiple sequence alignment program (6)

Oligonucleotide probes used in PCR-DNA hybridization assay
Oligonucleotide probes for detecting specific mycobacterial species were designed to be 15-17 nucleotide long, and to contain 10-11 G+C content (Table 2). However, the oligonucleotide probe for all the mycobacterial species (named as "Pan-TB" probe) was designed to be 20 nucleotide long. These specific oligonucleotide length and G+C content were selected, so that the hybridization conditions for each oligonucleotide to each mycobacterial DNA to be about the same.

Table 2. Oligonucleotide probes designed in this study to develop PCR-probe hybridization assay for Mycobacterial species identification

Name of oligonucleotides	Sequences of oligonucleotides	target mycobacteria
PAN-MYC	GACGTCGTCGCCACCATCGA	All mycobacterial species
TB	CATGTCGGCGAGCCC	<i>M. tuberculosis</i> complex
AVIUM	CGGTGAGCCGATCACCA	<i>M. avium</i>
INTRA	CCTGCACGCGGGCGA	<i>M. intracellulae</i>
GORDONAE	GTCGGCGATCCGATCA	<i>M. gordonae</i>
SZULGAI	TCTGAACGTCGGCGAG	<i>M. szulgai</i>
KANSASH	GGCCACGATGACCGTG	<i>M. kansasii</i>

GASTRI	TCTGAACGTCGGCGAG	<i>M. gastri</i>
FORTUITUM	CCTGAACGCCGGCCAG	<i>M. fortuitum</i>
FORTUITUM-COM	GTTCCGGTCGAGGTGG	<i>M. fortuitum complex</i>
SCROFULACEUM	CGTACGGATGGCCAGC	<i>M. scrofulaceum</i>
CHELONAE	TGGTGACTGCCACCACG	<i>M. chelonae</i>
ABSCESUS	AGGTGACCACCACCACC	<i>M. abscessus</i>
TERRAE	GCTCAGGACGGTCAGT	<i>M. terrae</i>
ULCERANS/MARINUM	GGCCAGCCCATCAC	<i>M. ulcerans / M. marinum</i>
GENAVANSE/SIMIAE	CCAGCCGACGATGACG	<i>M. genavense / M. simiae</i>

PCR-dot blot hybridization. To prepare the DNA dot blot, pre-cut (10x10cm²) membrane (Hybond-N⁺; Ammersham) was immersed into the denaturing solution (0.4N NaOH, 25 mM EDTA; pH 8.0) for 1 min. After dripping excess amount of denaturing solution, the membrane was placed on the 3MM paper, and 1-2 μ l of PCR product was blotted on the membrane. Then, the membrane was air-dried for 5 min, rinsed with the denaturing solution for another 1 min, placed in-between two sheets of 3MM papers, and baked for 2 hrs at 80°C. Oligonucleotide probes were labeled by using a commercially available kit for 3'-oligolabelling and detection (ECL, Amersham Life Science). Before hybridizing with oligonucleotide probes, membrane was prehybridized at 42°C for 30 min., and subsequently hybridized with 10pmol of labeled oligonucleotide probes at 42°C for 1hr. Then, the membrane was washed twice at room temperature for 20 min, and washed twice again at 52°C for 15min. Subsequent procedures including antibody binding, washing and the signal detection were all carried out by the method recommended by the manufacturer.

PCR-reverse blot hybridization. All oligonucleotide probes to be applied on the membrane were synthesized with 5' terminal amino group, which link the oligonucleotides to the Biotin C membrane (Pall BioSupport, East Hills, NY) by

forming covalent bond with negatively charged carboxyl group fixed on the membrane. Before blotting the oligonucleotide probes, the Biotodyne C membrane was activated by incubating in 10 ml of freshly prepared 16% (w/v) 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC). After rinsed with the water, the membrane was placed on a support cushion in a clean miniblotted system (Immunetics, Inc., Cambridge, MA), and the residual water was removed from the slots. Then, the slots were filled with 150 μ l of the diluted oligonucleotide solutions (approximately 200 pmol to 1 nmol of oligonucleotides in 150 μ l of 500 mM NaHCO₃, pH 8.4). Subsequently, the membrane was incubated for 1 hr at room temperature, and then excess amount of oligonucleotide solution was removed from the slots by aspiration. In order to inactivate the membrane, the membrane was removed from the miniblotted using forceps, incubated in 100 mM NaOH for 10 min in a rolling bottle, and washed in 100 ml 2x SSPE/0.1% SDS for 5 min at 60°C in a plastic container under gentle shaking. Before applying PCR products on the Biotodyne C membrane, the membrane was incubated for 5 min at room temperature in 100 ml 2x SSPE/0.1% SDS.

After placing the membrane on a support cushion into the miniblotted, in such a way that the slots were perpendicular to the line pattern of the applied oligonucleotides, residual fluid was removed from the slots by aspirations. For hybridization, about 10 μ l of PCR products were diluted in 150 μ l of 2x SSPE/0.1% SDS and heat-denatured for 10 min at 99°C and chilled immediately on ice. The slots were then filled with the diluted PCR products and the membrane was hybridized for 60 min at 42°C. Following hybridization, the membrane was washed in 2x SSPE/0.5% SDS for 10 min at 52°C, and incubated with 10 ml of 1:4000 diluted peroxidase labeled streptavidin conjugate in 2x SSPE/0.5% SDS for 30-60 min at 42°C in a rolling bottle. The membrane was then washed twice in 100 ml of 2x SSPE/0.5% SDS for 10 min at 42°C and rinsed twice with 100 ml of 2x SSPE for 5 min at room temperature. Finally for chemiluminescent detection of hybridizing DNA, the membrane was incubated for 1-2 min in 20 ml ECL detection liquid and

exposed to the x-ray film.

RESULTS

5 Since the genetic information for the *rpoB* genes of some mycobacteria are available, sequences were aligned and searched for regions, which are suitable for PRA. As a result, a set of PCR primer was selected to amplify 360-bp region of the *rpoB*, which contains polymorphic region flanked by conserved regions (Fig. 1. A.).

10 A total of 50 mycobacterial reference strains and 3 related bacterial strains that belong to the same Actinomycetes class with mycobacteria were used to amplify the 360-bp region of the *rpoB* gene (Table 1). The results showed the amplification of a conserved *rpoB* gene present in all mycobacteria and in some other bacteria such as *Nocardia* and *Rhodococcus* spp. (Fig. 1. B). Subsequently, PCR products were subjected to two sets of restriction enzyme digestion using *Msp* I and *Hae* III
15 individually. These two enzymes were selected on the basis of the sequence information of the *rpoB* gene in *M. tuberculosis*, *M. leprae*, and *M. smegmatis* (12, 13, 22).

Based on this information, PCR products were subsequently subjected for RFLP analysis (Fig. 2). In short, the result of this analysis showed that RFLP
20 profiles of PCR products from each mycobacteria species were distinctive each other. *M. kansasii* can be easily differentiated from *M. gastri* which has much in common with non-pigmented variants of *M. kansasii*. In addition, *M. abscessus*, which has been classified as a subgroup of *M. chelonae* and was not easy to be differentiated by conventional biochemical tests was also differentiated. Furthermore, for some
25 species, such as *M. fortuitum*, *M. cellatum*, *M. gordonae* and *M. kansasii* that are known to contain several subtypes, each subtype generated distinctive restriction profiles. Therefore, it clearly indicated that this new PRA method could differentiate mycobacterial species at the species and even at the subspecies level.

Variable RFLP profiles generated with PCR products strongly suggested to us the polymorphic nature of this *rpoB* region amplified by PCR in this study. Then, the next question was whether these variable RFLP profiles were species-specific or also strain-specific. If strains belonging to a certain species also show polymorphic RFLP profiles, it would be too complex to use this region for the mycobacterial species identification. Therefore, clinical isolates that have been identified on the basis of conventional tests were subjected for PRA to determine the species based on an algorithm made from this study by blind tests. The results from this experiment clearly show that there is no variation among different clinical isolates that belong to the same species (Fig. 3).

On the basis of the PRA and sequence analysis results, an algorithm was constructed (Fig. 4). In an algorithm, restriction fragments smaller than 40-bp were omitted in order to reduce the confusion with primer-dimer bands. The fragment sizes are clearly separated from each other, making interpretation of results easier. In brief, the algorithm clearly shows that most mycobacterial species and other related bacterial species can be differentiated at the subspecies level by PRA using *Msp* I and *Hae* III restriction enzymes. In fact, except for several mycobacterial species, most of species can be identified by using a single enzyme, *Msp* I, thus making this new method more useful for mycobacterial species identification than previously developed PRA methods.

For those strains that are not differentiated by two enzyme digestions, the third enzyme digestion was useful for differentiation. For example, even though the members of *M. tuberculosis* complex (*M. tuberculosis*, *M. bovis*, and *M. africanum*) were not differentiated by using *Msp* I and *Hae* III, the third enzyme *Sau* 3AI can differentiate *M. africanum* from other members of *M. tuberculosis* complex. In other cases, *Hinc* II can differentiate *M. gordonae* type I from *M. celatum* type I, and etc.

Subsequently, a substantial number of clinical isolates that have been identified on the basis of conventional tests were subjected for PRA (Table 3). In this

experiment, a total of 260 clinical isolates were analyzed including *M. tuberculosis*, *M. avium*, *M. intracellulare*, *M. fortuitum*, *M. chelonae*, *M. abscessus*, *M. terrae*, *M. gordonae*, *M. szulgai*, etc. For the easy interpretation of the PRA profiles generated by each clinical isolates, a 50-bp ladder size marker was used as a standard size marker, and the PRA profile of *M. bovis* was used as an internal size marker (Fig. 5). Results from the PRA of clinical isolates were evaluated with the help of an algorithm generated on the basis of PRA profiles of reference strains. Most of the PRA results were consistent with conventional test results, while PRA profiles of a few strains were not present in the reference algorithm. Based on the conventional tests and molecular biological sequence analysis, some of these were determined to be "*M. terrae* complex."

Table 3. Clinical isolates of mycobacteria subjected for the species identification using the new PRA.

Species Tested	No. of Clinical Isolates
<i>M. tuberculosis</i>	40
<i>M. avium</i>	40
<i>M. intracellulare</i>	50
<i>M. gordonae</i>	25
<i>M. szulgai</i>	10
<i>M. fortuitum</i>	25
<i>M. chelonae</i>	15
<i>M. abscessus</i>	15
<i>M. kansasii</i>	20
<i>M. terrae</i>	20
Total	260

Next, we sequenced PCR amplified region of the *rpoB* gene derived from 30 mycobacterial species that are known to have clinical importance. Subsequently, the sequences of the amplified regions were analyzed by using a software program (6).
5 The result of the sequence analysis clearly showed that in the region of the *rpoB* we amplified, highly polymorphic regions exist, which are highly species-specific (Fig. 6). This observation suggested to us that this highly polymorphic region of the *rpoB* can be very useful to design mycobacterial species-specific oligonucleotide probes, which can be used for developing a new PCR-dot blot hybridization technique for
10 mycobacterial species identification. Subsequently, based on the sequence information, species-specific oligonucleotide was designed (Table 3), and each oligonucleotide was used as a probe in PCR-dot blot hybridization (Fig. 7). In this experiment, a total of 48 mycobacterial species were blotted on the membrane, and each oligonucleotide was used as a probe to detect specific mycobacterial species. In
15 brief, the results showed that each oligonucleotide probe was shown to be highly specific to each mycobacterial species targeted, indicating the usefulness of oligonucleotides for developing probe-based mycobacterial identification systems such as PCR-dot blot hybridization and PCR-reverse blot hybridization techniques.

Subsequently these probes were used to make a reverse-blot which can be used
20 for the mycobacterial species identification system by using PCR-reverse blot hybridization method. The results showed that the PCR-reverse blot hybridization method employing each mycobacterial species-specific oligonucleotide probes are very efficient system for identification of mycobacteria.

25 All documents cited in the specification and as references below are hereby incorporated in their entirety by reference.

REFERENCES

1. Abed, Y., C. Bollet, and P. de Micco. 1995. Demonstration of
 Mycobacterium kansasii species heterogeneity by the amplification of the 16S-
5 23S spacer region. J. Med Microbiol. 43:156-158.
2. Avaniss-Aghajani, E., K. Jones, A. Holtzman, T. Aronson, N. Glover, M.
 Bofan, S. Froman, and C. F. Brunk. 1996. Molecular technique for rapid
 identification of mycobacteria. J. Clin. Microbiol. 34:98-102.
3. Böddinghaus, B., T. Rogall, T. Flohr, H. Blöcker, and E. C. Böttger.
10 1990. Detection and identification of mycobacteria by amplification of rRNA. J.
 Clin. Microbiol. 28:1751-1759.
4. Bosne, S., and V. Lévy-Frébault. 1992. Mycobactin analysis as an aid for
 the identification of *Mycobacterium fortuitum* and *Mycobacterium chelonae*
 subspecies. J. Clin. Microbiol. 30:1225-1231.
- 15 5. Butler, W. R., K. C. Jost, Jr., and J. O. Kilburn. 1991. Identification of
 mycobacteria by high-performance liquid chromatography. J. Clin. Microbiol.
 29:2468-2472.
6. Corpet. F. 1988. Multiple sequence alignment with hierarchical clustering.
 Nucl. Acids. Res. 16: 10881-10890.
- 20 7. Devallois A., K. S. Goh, and N. Rastogi. 1997. Rapid identification of
 Mycobacteria to species level by PCR-restriction fragment length polymorphism
 analysis of the *hsp65* gene and proposition of an algorithm to differentiate 34
 mycobacterial species. J. Clin. Microbiol. 35:2969-2973.
8. Fiss, E., F. Chehab, and G. Brooks. 1992. DNA amplification and reverse
25 dot blot hybridization for detection and identification of mycobacteria to the
 species level in the clinical laboratory. J. Clin. Microbiol. 30:1220-1224.
9. Fries, J., R. Patel, W. Piessens, and D. Wirth. 1990. Genus- and species-
 specific DNA probes to identify mycobacteria using the polymerase chain

- reaction. Mol. Cell. Probes. 4:87-105.
10. Gingeras, T. R., G. Ghandour, E. Wang, A. Berno, P. M. Small, F. Drobniewski, D. Alland, E. Desmond, M. Holokniy, and J. Drenkow. 1998. Simultaneous genotyping and species identification using hybridization pattern
5 recognition analysis of generic *Mycobacterium* DNA arrays. Genome Res. 8:435-448.
11. Hance, A. J., B. Grandchamp, V. Lévy-Frébault, D. Lecossier, J. Rauzier, D. Bocart, and B. Gicquel. 1989. Detection and identification of mycobacteria by amplification of mycobacterial DNA. Mol. Microbiol. 3:843-
10 849.
12. Hetherington, S. V., A. S. Watson, and C. C. Patrick. 1995. Sequence and analysis of the *rpoB* gene of *Mycobacterium smegmatis*. Antimicrob. Agents Chemother. 39:2164-2166.
13. Honore, N. T., S. Bergh, S. Chanteau, F. Doucet-Populaire, K. Elglmeier, T. Garnier, C. Geroges, P. Launois, T. Limpaiiboon, S. Newton, K.
15 Niang, P. Del Portillo, G. R. Ramesh, P. Reddi, P. R. Ridel, N. Sittisombut, S. Wu-Hunter, and S. T. Cole. 1993. Nucleotide sequence of the first cosmid from the *Mycobacterium leprae* genome project: structure and function of the Rif-Str regions. Mol. Microbiol. 7:207-214.
- 20 14. Hughes, M. S., R. A. Skuce, L. -A. Beck, and S. D. Neill. 1993. Identification of mycobacteria from animals by restriction enzyme analysis and direct DNA cycle sequencing of polymerase chain reaction-amplified 16S rRNA gene sequences. J. Clin. Microbiol. 31:3216-3222.
15. Kapur, V., L.-L. Li, M. R. Hamrick, B. B. Plikaytis, T. M. Shinnick, A. Telenti, W. R. Jacobs, A. Banerjee, S. Cole, K. Y. Yuen, J. E. Clarridge, B. N. Kreiswirth, and J. M. Musser. 1995. Rapid *Mycobacterium* species assignment and unambiguous identification of mutations associated with antimicrobial resistance in *Mycobacterium tuberculosis* by automated DNA

- sequencing. Arch. Pathol. Lab. Med. 119:131-138.
16. Kim, B. -J., S. -H. Lee, M. -A. Lyu, S. -J. Kim, G. -H. Bai, S. -J. Kim, G. -
T. Chae, E. -C. Kim, C. -Y. Cha, and Y. -H. Kook. 1999. Identification of
Mycobacterial species by comparative sequence analysis of the RNA polymerase
5 gene (*rpoB*). J. Clin. Micro. 37:1714-1720.
17. Kirschner, P., B. Springer, U. Vogel, A. Meier, A. Wrede, M.
Kickenbeck, F.-C. Bange, and E. C. Böttger. 1993. Genotypic identification of
mycobacteria by nucleic acid sequence determination: report of a 2-year
experience in a clinical laboratory. J. Clin. Microbiol. 31:2882-2889.
- 10 18. Kusunoki, S., T. Ezaki, M. Tamesada, Y. Hatanaka, K. Asano, Y.
Hashimoto, and E. Yabuuchi. 1991. Application of colorimetric microdilution
plate hybridization for rapid genetic identification of 22 *Mycobacterium* species.
J. Clin. Microbiol. 29:1596-1603.
19. Lévy-Frébault V., M. Daffé, K. S. Goh, M.-A. Lanéelle, C. Asselineau,
15 and H. L. David. 1983. Identification of *Mycobacterium fortuitum* and
Mycobacterium chelonae. J. Clin. Microbiol. 17:744-752.
20. Mabilat, C., S. Desvarenne, G. Panteix, N. Machabert, M.-H. Bernillon,
G. Guardiola, and P. Cros. 1994. Routine identification of *Mycobacterium*
tuberculosis complex isolates by automated hybridization. J. Clin. Microbiol.
20 32:2702-2705.
21. Marks, J., and T. Szulga. 1965. Thin-layer chromatography of
mycobacterial lipids as an aid to classification; technical procedures;
Mycobacterium fortuitum. Tubercle 46:400-411.
22. Miller, L. P., J. T. Crawford, and T. M. Shinnick. 1994. The *rpoB* gene
of *Mycobacterium tuberculosis*. Antimicrob. Agents Chemother. 38:805-811.
- 25 23. Musial, C., L. Tice, L. Stockman, and G. Roberts. 1988. Identification of
mycobacteria from culture by using the Gen-probe rapid diagnostic system for
Mycobacterium avium complex and *Mycobacterium tuberculosis* complex. J.

- Clin. Microbiol. 26:2120-2123.
24. Picaudeau, M., G. Prod'homme, L. Raskine, M. P. LePennec, and V. Vincent. 1997. Genotypic characterization of five subspecies of *Mycobacterium kansasii*. J. Clin. Microbiol. 35:25-32.
- 5 25. Plikaytis, B. B., B. D. Plikaytis, M. A. Yakrus, W. R. Butler C. L. Woodley, V. A. Silcox, and T. M. Shinnick. 1992. Differentiation of slowly growing *Mycobacterium* species, including *Mycobacterium tuberculosis*, by gene amplification and restriction fragment length polymorphism analysis. J. Clin. Microbiol. 30:1815-1822.
- 10 26. Rogall, T., T. Flohr, and E. Bottger. 1990. Differentiation of mycobacterial species by direct sequencing of amplified DNA. J. Gen. Microbiol. 136:1915-1920.
27. Ross, B. C., K. Jackson, M. Yang, A. Sievers, and B. Dwyer. 1992. Identification of a genetically distinct subspecies of *Mycobacterium kansasii*. J. Clin. Microbiol. 30:2930-2933.
- 15 28. Shinnick, D. and H. Yeager, Jr. 1999. Nontuberculous mycobacterial infection: clinical syndromes and diagnosis: overview. p341-350. In D. Schlossberg (ed.), Tuberculosis and nontuberculous mycobacterial infections, 4th ed. W. B. Saunders Co., Philadelphia. PA.
- 20 29. Shinnick, T. M. 1987. The 65-kilodalton antigen of *Mycobacterium tuberculosis*. J. Bacteriol. 169:1080-1088.
30. Shinnick, T. M., M. H. Vodkin, and J. C. Williams. 1988. The *Mycobacterium tuberculosis* 65-kilodalton antigen is a heat shock protein which corresponds to common antigen and to the *Escherichia coli* GroEL protein.
- 25 Infect. Immun. 56:446-451.
31. Soini, H., E. C. Böttger, and M. K. Viljanen. 1994. Identification of mycobacteria by PCR-based sequence determination of the 32-kilodalton protein gene. J. Clin. Microbiol. 32:2944-2947.

32. Springer, B., L. Stockman, K. Teschner, G. D. Roberts, and E. C. Böttger. 1996. Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. *J. Clin. Microbiol.* 34:296-303.
- 5 33. Takewaki, S.-I., K. Okuzumi, I. Manabe, M. Tanimura, K. Miyamura, K.-I. Nakahara, Y. Yazaki, A. Ohkubo, and R. Nagai. 1994. Nucleotide sequence comparison of the mycobacterial *dnaJ* gene and PCR-restriction fragment length polymorphism analysis for identification of mycobacterial species. *Int. J. Syst. Bacteriol.* 44:159-166.
- 10 34. Taylor, T. B., C. Patterson, Y. Hale, and W. W. Safranek. 1997. Routine use of PCR-restriction fragment length polymorphism analysis for identification of mycobacteria growing in liquid media. *J. Clin. Microbiol.* 35:79-85.
35. Telenti, A., F. Marchesi, M. Balz, F. Bally, E. C. Böttger, and T. Bodmer. 1993. Rapid identification of mycobacteria to the species level by
15 polymerase chain reaction and restriction enzyme analysis. *J. Clin. Microbiol.* 31:175-178.
36. Tsang, A., I. Drupa, M. Goldgerg, J. McClatchy, and P. Brennan. 1983. Use of serology and thin-layer chromatography for the assembly of an authenticated collection of serovars within the *Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum* complex. *Int. J.*
20 *Syst. Bacteriol.* 33:285-292.
37. Vaneechoutte, M., H. D. Beenhouwer, G. Claeys, G. Verschraegen, A. D. Rouk, N. Paepe, A. Elaichouni, and F. Portaels. 1993. Identification of *Mycobacterium* species by using amplified ribosomal DNA restriction analysis. *J.*
25 *Clin. Microbiol.* 31:2061-2065.

CLAIMS

1. A DNA fragment which has one of the sequence Seq. ID. NO 1 to 4 or 6 to 24
2. A method of diagnosis and identification Mycobacterium strain comprising the
step of
 - a) digesting a DNA fragment which has one of the sequence Seq. ID. NO 1 to
4 or 6 to 24 with restriction enzyme to obtain DNA fragment length
polymorphism pattern ;
 - b) isolating DNA fragment from microorganism to identify;
 - c) amplifying said DNA fragment;
 - d) digesting said amplified DNA fragment with the same restriction enzyme in
step a) ;
 - e) obtaining DNA fragment length polymorphism pattern from DNA fragment
in step d) ; and
 - f) comparing DNA fragment length polymorphism pattern from step a) with
DNA fragment length polymorphism pattern from step e).
3. A method of claim 2, wherein said DNA fragment length polymorphism from
step a) and step e) are characterized as obtaining by electrophoresis.
4. A method of claim 3, wherein said restriction enzyme is characterized as *HaeIII*,
MspI, *Sau3A1* or *BstEII*.
5. A method of one of the claims 2 to 4, wherein said Mycobacteria strain is
characterized as *M. tuberculosis*, *M. avium*, *M. abscessus*, *M. flavescent*, *M. africanum*,
M. bovis, *M. chelonae*, *M. celatum*, *M. fortuitum*, *M. gordonae*, *M. gastri*,
M. haemophilum, *M. intracellulare*, *M. kansasii*, *M. malmoense*, *M. marinum*,
M. szulgai, *M. terrae*, *M. scrofulaceum*, *M. ulcerans* or *M. xenopii*.

1/11

FIG. 1a




FIG. 1b



2/11

FIG. 2a**FIG. 2b**

3/11

FIG. 3a



FIG. 3b




4/11

FIG. 3c




5/11

FIG. 4



6/11

FIG. 5




9/11

FIG. 7a

1	2	3	4	5	6
7	8	9	10	11	12
13	14	15	16	17	18
19	20	21	22	23	24
25	26	27	28	29	30
31	32	33	34	35	36
37	38	39	40	41	42
43	44	45	46	47	48

10/11

FIG. 7b



1	2	3	4	5	6
7	8	9	10	11	12
13	14	15	16	17	18
19	20	21	22	23	24
25	26	27	28	29	30
31	32	33	34	35	36
37	38	39	40	41	42
43	44	45	46	47	48

11/11

FIG. 7c

1	2	3	4	5	6
7	8	9	10	11	12
13	14	15	16	17	18
19	20	21	22	23	24
25	26	27	28	29	30
31	32	33	34	35	36
37	38	39	40	41	42
43	44	45	46	47	48

SEQUENCE LISTING

<110> ERUME BIOTECH CO., LTD.

<120> rpoB GENE FRAGMENTS AND A METHOD FOR THE DIAGNOSIS AND IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOSIS MYCOBACTERIAL STRAINS

<130> PUS-001027

<150> KR1999-46795

<151> 1999-10-27

<160> 26

<170> PatentIn version 3.0

<210> 1

<211> 208

<212> DNA

<213> Mycobacterium gordonae I

<400> 1

```
tcaaggagaa gcgctacgac ctggcccggg taggccccta caaggtcaac aagaagctcg      60
gcctgcacgt cggcgatccg atcaccagct ccacgtgac cgaggaagac gtcgtcgcca      120
ccatcgagta cctggtcgcg ctgcacgagg gccagcacac gatgaccgtc cccggcgcca      180
ccgaggtgcc ggttgagacc gacgacat                                           208
```

<210> 2

<211> 208

<212> DNA

<213> Mycobacterium gordonae II

<400> 2

```
tcaaggagaa gcgctacgac ctggcccggg tggcgcccta caaggtcaac aagaagctcg      60
gtctgaacgt cggcaagccg atcaccagct cgacgtgac cgaggaagac gtcgtagcca      120
ccatcgagta cctggtcggg ctgcacgagg gtcagtcggc gatgacggtt cccggcgccg      180
ccgaggtgcc ggttgagacc gacgacat                                           208
```

<210> 3

<211> 208
 <212> DNA
 <213> *Mycobacterium gordonae* III

<400> 3
 tcaaggagaa gcgctacgac ctggcccgtg tggccgcta caaggtcaac aagaagctcg 60
 gcctgcacgt cggcgatccg atcaccagct ccacgtgac cgaagaagac gtcgtcgcca 120
 ccatacgagta cctggtcggt ctgcacgagg gtcagcacac gatgaccgtt cggggcgcca 180
 ccgaggttcc ggtggagacc gacgacat 208

<210> 4
 <211> 207
 <212> DNA
 <213> *Mycobacterium gordonae* IV

<400> 4
 tcaaggagaa gcgctacgac ctggcccgtg tggccgcta caaggtcaac aagaagctgg 60
 gcctgcacgt cggcgatccg atcaccagct ccacgtgac cgaagaggac gtcgtcgcca 120
 ccatacgagta cctggtcggt ctccacgagg gtcagcacac gatgaccgtt cggggcgggc 180
 cgaggttccg gttggagacc acgacat 207

<210> 5
 <211> 208
 <212> DNA
 <213> *Mycobacterium tuberculosis*

<400> 5
 tcaaggagaa gcgctacgac ctggcccgtg tggctcgcta taaggtcaac aagaagctcg 60
 ggctgcacgt cggcgagccc atcagctcgt ccacgtgac cgaagaagac gtcgtcgcca 120
 ccatacgagta tctggtcggt ttgcacgagg gtcagaccac gatgaccgtt cggggcgggc 180
 tcgaggtgcc ggtggaaacc gacgacat 208

<210> 6
 <211> 208
 <212> DNA
 <213> *Mycobacterium terrae*

<400> 6
 tcaaggagaa gcgctacgac ctggcccgcg tcggtcgcta taaggtaac aagaagctcg 60
 ggctgcatgt cggcgagccc atcacgtcgt cgacgtgac cgaagaagac gtcgtggcca 120
 ccatcgaata tctggtccgc ttgcacgagg gtcagaccac gatgaccgtt ccggcgcgcg 180
 tcgaggtgcc ggtggaaacc gacgacat 208

<210> 7
 <211> 214
 <212> DNA
 <213> *Mycobacterium chelonae*

<400> 7
 tcaaggagaa gcgctacgac ctggcccgcg tggcgcgcta caaggtaac aagaagctgg 60
 gtcttggcgg tgccaacccg gctctgggtga ctgccaccac gctcaccgag gaagacgtcg 120
 tcgccaccat cgggtacctg gtgcgcctgc acgagggccca gaccacgatg accgcccccg 180
 gcggcctcga ggtcccggtc gaggtcgacg acat 214

<210> 8
 <211> 208
 <212> DNA
 <213> *Mycobacterium kansasii*

<400> 8
 tcaaggagaa gcgctacgac ctggcccgtg tcggccgata caaggtaac aagaagctgg 60
 gcctgaacac caatcatccg atcaccacga cgacgtgac cgaagaagac gtcgtcgcca 120
 ccatcgagta tctggtccgc ctgcacgagg gccaggccac gatgaccgtg ccggcgcggg 180
 tcgaggtgcc ggtggaaacc gacgacat 208

<210> 9
 <211> 223
 <212> DNA
 <213> *Mycobacterium scrofulaceum*

<400> 9
 tcaaggagaa gcgctacgac ctggcccgcg tcggccgcta caaggtaac aagaagctgg 60

gtctgcagcg cggcgagccg atcacgtcgt ccacgtgac cgaggaagac gtcgtcgcga 120
 ccacgaata cctgggtccgg ctgcaccacg cccgtacgga tggccagccc gccgtcatga 180
 ctgtccccgg cggcatcgag gtgccggtgg agaccgacga cat 223

<210> 10
 <211> 208
 <212> DNA
 <213> *Mycobacterium ulcerans*

<400> 10
 tcaaggagaa gcgctacgac ctggctcgcg tgggtcggtg caaggtcaac aagaagctcg 60
 gcctgaacgc cggccagccc atcaccagct cgacgtgac cgaggaagac gtcgtcgcca 120
 ccacgaata cctgggtccg ttgcacgagg gccagaccgc gatgaccgct cggggcggtg 180
 tcgaggtgcc ggtcgagacc gacgacat 208

<210> 11
 <211> 208
 <212> DNA
 <213> *Mycobacterium marinum*

<400> 11
 tcaaggagaa gcgctacgac ctggcccggg tgggccggtg caaggtcaac aagaagctcg 60
 gcctgaacgc cggccagccc atcaccagct cgacgtgac cgaggaagac gtcgtcgcca 120
 ccacgaata cctgggtccg ttgcacgagg gccagaccgc gatgaccgct cggggcggtg 180
 tcgaggtgcc ggtcgagacc gacgacat 208

<210> 12
 <211> 207
 <212> DNA
 <213> *Mycobacterium szulgai*

<400> 12
 tcaaggagaa gcgctacgac ctggctcgct cggccgttac aaggtcaaca aaaagctcgg 60
 tctgaacgtc ggcgagccga tcaccagttc gacgtgacc gaagaggatg tcgtgccac 120

catcgagtag ctggttcggc tgcacgaggc ccagaccacg atgaccgttc cggcgggcac 180
cgaggtgccg gtggagaccg acgacat 207

<210> 13
<211> 223
<212> DNA
<213> *Mycobacterium gastris*

<400> 13
tcaaggagaa gcgctacgac ctggcccgcg tggccgcta caaggtcaac aagaagctgg 60
gcctgaacac cgatcatccg atcaccacca cgacgtgac cgaagaagac gtcgtcgcca 120
ccatcgagta cctggttcgc ctgcaccacg cctctcaggc tggccaggcc cccgttatga 180
ctgtccccgc cggggtcgag gtgccggtgg aaaccgacga cat 223

<210> 14
<211> 214
<212> DNA
<213> *Mycobacterium malmoense*

<400> 14
tcaaggagaa gcgctacgac ctggccaggc ttggccgcta caaggtcaac aagaagctcg 60
ggctgcgggc ggccgagtcg gccgtaccgc cctcgaccac gctgaccgaa gcggatgtcg 120
tcgccaccat cgagtagctg gtgcgcctgc acgaggcca ggcaacgatg acggttcccg 180
gcggcgctga ggtgccggtg gagaccgacg acat 214

<210> 15
<211> 208
<212> DNA
<213> *Mycobacterium avium*

<400> 15
tcaaggagaa gcgctacgac ctggcccggc tggccgcta caaggtcaac aagaagctcg 60
gcctgcacgc cggtagccg atcaccagct cgacgtgac cgaggaagac gtcgtcgcca 120
ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc cccggcgcca 180
tcgaggtgcc ggtggagacc gacgacat 208

<210> 16
 <211> 208
 <212> DNA
 <213> *Mycobacterium bovis*

<400> 16
 tcaaggagaa gcgctacgac ctggcccgcg tgggtcgcta taaggtcaac aagaagctcg 60
 ggctgcatgt cggcgagccc atcacgtcgt cgacgtgac cgaagaagac gtcgtggcca 120
 ccatcgaata tctgggtccg tgcacgagg gtcagaccac gatgaccgtt ccgggcggcg 180
 tcgaggtgcc ggtggaaacc gacgacat 208

<210> 17
 <211> 208
 <212> DNA
 <213> *Mycobacterium celatum*

<400> 17
 tcaaggagaa gcgctacgac ctgcgcggg tgggccgcta caaggtcaac aagaagctcg 60
 gcctgaacac cgctcccg atcacgacga ccactctgac cgaagaggac gtcgtgccca 120
 ccatcgagta cctgggtccg ctgcacgagg gccacaccac gatgaccgtc ccgggcggag 180
 tcgaggtgcc ggtggaaacc gacgacat 208

<210> 18
 <211> 211
 <212> DNA
 <213> *Mycobacterium flavescens*

<400> 18
 tcaaggagaa gcgctacgac ctggcccgcg tgggtcgcta caaggtcaac aagaagctcg 60
 gcatcaccga gaacccggcc gacacgacct cgaccacgt gaccgaagag gacgtcgtcg 120
 ccaccatga gtacctgtg cggctgcatc agggcgacaa gacgatgacc gtcccggtg 180
 gagtcgaggt gccctgcgag gtcgacgaca t 211

<210> 19

<211> 208
 <212> DNA
 <213> *Mycobacterium fortuitum*

<400> 19
 tcaaggagaa gcgtacgac ctggcccgcg tgggccgcta caaggtcaac aagaagctgg 60
 gcctgaacgc cggccagccg atcacgtcgt cgactctgac cgaggaagac gtcgtcgcca 120
 ccatcgagta cctggtgcgc ctgcacgagg gccagaccac gatgaccgtc cccggcggcg 180
 tcgaggtccc ggtcgagggtg gacgacat 208

<210> 20
 <211> 205
 <212> DNA
 <213> *Mycobacterium intracellulare*

<400> 20
 tcaaggagaa gcgtacgac ctggcgcgtg tgggccgcta caaggtcaac aagaagctcg 60
 gcctgcacgc gggcgagccg atcaccagct cgacgtgac cgaggaagac gtcgtcgcca 120
 ccatcgagta cctggtgcgc ctgcacgagg gccagcccac gatgaccgtc cccggcatcg 180
 aggtgccggt ggagaccgac gacat 205

<210> 21
 <211> 214
 <212> DNA
 <213> *Mycobacterium abscessus*

<400> 21
 tcaaggagaa gcgtacgat ctggcccgcg tgggtcggta caaggtgaac aagaagctgg 60
 gcctggcgcg caccaatccg gctcaggtga ccaccaccac cctcaccgag gaagacgtcg 120
 tcgccaccat cgagtacgtg gtgcgcctgc acgagggccca gaccacgatg accgcccccg 180
 gcggcgtcga ggtgccgggtg gatgtggacg acat 214

<210> 22
 <211> 208
 <212> DNA
 <213> *Mycobacterium africanum*

<400> 22
 tcaaggagaa gcgctacgac ctggcccgcg tcggtcgcta taaggtaac aagaagctcg 60
 ggctgcatgt cggcgagccc atcacgtcgt cgacgtgac cgaagaagac gtcgtggcca 120
 ccatcgaata tctggtcgcg ttgcacgagg gtcagaccac gatgatcggt cggggcgcg 180
 tcgaggtgcc ggtggaaacc gacgacat 208

<210> 23
 <211> 208
 <212> DNA
 <213> Mycobacterium haemophilum

<400> 23
 tcaaggagaa gcgctacgac ctggcccggg ttggtcgcta caaggtaac aagaagctcg 60
 ggttcacgc cggtagccg atcacgagct cgacgtgac cgaagaggac gtcgtgccca 120
 ccatcgagta cctggtcgcg ctgcatgagg gtcagtcgac gatgaccgtt ccaggtagcg 180
 tcgaggtgcc agtggatact gacgacat 208

<210> 24
 <211> 208
 <212> DNA
 <213> Mycobacterium xenopi

<400> 24
 tcaaggagaa gcgctacgac ctggcccggg tggccgcta caaggtaac aagaagctcg 60
 ggctgaacac cgagaatcgc ccaaccacca cgaccctgac cgaagaggac gtcgtgccca 120
 ccatcgaata cctggtcgcg ttgcacgagg ggcacgccac gatgaagtc cccggtggcg 180
 tcgaggtgcc ggtggagacc gacgacat 208

<210> 25
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<400> 25
 tcaaggagaa gcgctacga 19

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 26
ggatgttgat cagggtctgc

20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 00/01223

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C12Q 1/68

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CAS, STN-registry

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95/33074 A1 (MAYO FOUNDATION FOR MEDICAL EDUCATION) 7 December 1995 (07.12.95) claim 1.	2,3,5
A	WO 95/33851 A2 (INNOGENETICS N-V-) 14 December 1995 (14.12.95) claim 1.	2,3,5
A	WO 99/05316 A1 (BIONEER CORPORATION) 4 February 1999 (04.02.99) abstract.	2,3,5

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

..A" document defining the general state of the art which is not

considered to be of particular relevance

..E" earlier application or patent but published on or after the international

filing date

..L" document which may throw doubts on priority claim(s) or which is

cited to establish the publication date of another citation or other

special reason (as specified)

..O" document referring to an oral disclosure, use, exhibition or other

means

..P" document published prior to the international filing date but later than

the priority date claimed

..T" later document published after the international filing date or priority

date and not in conflict with the application but cited to understand

the principle or theory underlying the invention

..X" document of particular relevance; the claimed invention cannot be

considered novel or cannot be considered to involve an inventive step

when the document is taken alone

..Y" document of particular relevance; the claimed invention cannot be

considered to involve an inventive step when the document is

combined with one or more other such documents, such combination

being obvious to a person skilled in the art

..&" document member of the same patent family

Date of the actual completion of the international search

5 February 2001 (05.02.2001)

Date of mailing of the international search report

27 February 2001 (27.02.2001)

Name and mailing address of the ISA/AT

Austrian Patent Office

Kohlmarkt 8-10; A-1014 Vienna

Facsimile No. 1/53424/535

Authorized officer

MOSSER

Telephone No. 1/53424/437

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 00/01223

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	A1	9533074	07-12-1995	AU	A1 26057/95	21-12-1995
				US	A 5643723	01-07-1997
WO	A2	9533851	14-12-1995	AU	A1 27896/95	04-01-1996
WO	A3	9533851	08-02-1996	AU	B2 703947	01-04-1999
				BR	A 9507960	02-09-1997
				CZ	A3 9603612	16-07-1997
				EP	A1 771360	07-05-1997
				JP	T2 10500857	27-01-1998
WO	A1	9905316	04-02-1999	AU	A1 84648/98	16-02-1999
				KR	B1 234975	15-12-1999